Stock BETA BETA DRUGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beta Drugs Limited

Equities

BETA

INE351Y01019

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 05:13:48 10/05/2024 pm IST 		5-day change 1st Jan Change
1,271 INR -0.94% Intraday chart for Beta Drugs Limited -5.71% -13.56%
2023 Beta Drugs Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
2023 Beta Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 1,090 905.6 346 1,038 5,437 6,027
Enterprise Value (EV) 1 1,047 1,077 517.8 1,108 5,469 6,039
P/E ratio 16.1 x 11.3 x 4.03 x 9.84 x 21.9 x 19.6 x
Yield - - - - - -
Capitalization / Revenue 2.16 x 1.37 x 0.38 x 0.89 x 2.96 x 2.65 x
EV / Revenue 2.07 x 1.63 x 0.57 x 0.95 x 2.98 x 2.66 x
EV / EBITDA 11.1 x 9.07 x 2.87 x 4.51 x 12.9 x 11.4 x
EV / FCF -13.6 x -4.49 x -6.86 x 15.6 x 7,627 x -344 x
FCF Yield -7.34% -22.3% -14.6% 6.41% 0.01% -0.29%
Price to Book 3.31 x 2.21 x 0.67 x 1.68 x 5.89 x 4.9 x
Nbr of stocks (in thousands) 8,650 8,650 8,650 8,650 9,614 9,614
Reference price 2 126.0 104.7 40.00 120.0 565.5 627.0
Announcement Date 17/08/18 05/09/19 31/08/21 31/08/21 27/04/22 05/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 505.7 659.3 908.1 1,161 1,838 2,271
EBITDA 1 94.56 118.7 180.5 245.9 424.4 529.9
EBIT 1 76.06 90.26 142.9 179.1 354.4 430.3
Operating Margin 15.04% 13.69% 15.74% 15.43% 19.28% 18.94%
Earnings before Tax (EBT) 1 68.36 79.06 119.7 159.5 343 410.6
Net income 1 67.64 80.4 94.15 117.2 248.3 307.2
Net margin 13.38% 12.19% 10.37% 10.1% 13.51% 13.53%
EPS 2 7.820 9.295 9.930 12.20 25.82 31.95
Free Cash Flow 1 -76.83 -239.7 -75.46 71 0.7171 -17.57
FCF margin -15.19% -36.36% -8.31% 6.11% 0.04% -0.77%
FCF Conversion (EBITDA) - - - 28.87% 0.17% -
FCF Conversion (Net income) - - - 60.56% 0.29% -
Dividend per Share - - - - - -
Announcement Date 17/08/18 05/09/19 31/08/21 31/08/21 27/04/22 05/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - 171 172 70.4 32.8 11.7
Net Cash position 1 42.3 - - - - -
Leverage (Debt/EBITDA) - 1.44 x 0.952 x 0.2862 x 0.0773 x 0.0221 x
Free Cash Flow 1 -76.8 -240 -75.5 71 0.72 -17.6
ROE (net income / shareholders' equity) 34.7% 21.8% 19.2% 18.7% 30.9% 28.5%
ROA (Net income/ Total Assets) 13.1% 8.54% 9.42% 9.97% 16.1% 15.1%
Assets 1 517.9 941.4 1,000 1,176 1,543 2,035
Book Value Per Share 2 38.00 47.30 59.40 71.40 96.10 128.0
Cash Flow per Share 2 13.80 3.820 5.600 10.80 18.00 19.90
Capex 1 82.8 207 153 57.6 194 182
Capex / Sales 16.37% 31.35% 16.85% 4.96% 10.57% 8.02%
Announcement Date 17/08/18 05/09/19 31/08/21 31/08/21 27/04/22 05/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
BETA DRUGS LIMITED Stock Beta Drugs Limited
-13.56% 148M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.76% 695B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.62% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.87% 330B
ABBVIE INC. Stock AbbVie Inc.
+3.70% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.79% 239B
NOVARTIS AG Stock Novartis AG
+8.32% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-7.85% 198B
AMGEN INC. Stock Amgen Inc.
+8.57% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BETA Stock
  4. Financials Beta Drugs Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW